HAIC Combined With Sintilimab Plus Bevacizumab Biosimilar for Advanced Hepatocellular Carcinoma (TASK-03)

NCT06860490 · clinicaltrials.gov ↗

PHASE2

Phase

RECRUITING

Status

164

Enrollment

OTHER

Sponsor class

Conditions

Hepatocellular Carcinoma (HCC)

Interventions

DRUG: Sintilimab
DRUG: Bevacizumab Biosimilar
PROCEDURE: HAIC

Sponsor

Fudan University